Fadem Stephen Z, Moe Sharon M
Baylor College of Medicine, Division of Nephrology, Houston, TX, USA.
Adv Chronic Kidney Dis. 2007 Jan;14(1):44-53. doi: 10.1053/j.ackd.2006.10.004.
Chronic kidney disease mineral-bone disorder (CKD-MBD) is a systemic disorder of abnormal serum levels of mineral-related biochemistries, abnormal bone, and extraskeletal calcification. Although we have gained understanding on how these components are interrelated, our therapeutic tools remain focused on only one aspect of CKD-MBD at a time. However, the management of these disorders is also interrelated; treatments may help one aspect of the disorder but cause or accelerate another. As such, management remains a major challenge to nephrologists and requires balancing risk and benefit of the various available therapies. Our challenge for the decade ahead is to determine which combinations of therapy can be used safely together to prevent morbidity and mortality in CKD. Furthermore, the pathophysiology that sets these events into motion begins well before the onset of ESRD. Future therapies and guidelines should, therefore, also emphasize the need for earlier detection and management of CKD, shaped by the results of valid clinical trials.
慢性肾脏病矿物质-骨异常(CKD-MBD)是一种系统性疾病,表现为与矿物质相关的血清生物化学指标异常、骨骼异常以及骨外钙化。尽管我们已经了解了这些组成部分之间的相互关系,但我们的治疗手段一次仅聚焦于CKD-MBD的一个方面。然而,这些疾病的管理也是相互关联的;治疗可能有助于疾病的一个方面,但会引发或加速另一个方面。因此,管理仍然是肾病学家面临的一项重大挑战,需要权衡各种可用疗法的风险和益处。我们未来十年面临的挑战是确定哪些治疗组合可以安全地联合使用,以预防CKD患者的发病和死亡。此外,引发这些事件的病理生理学早在终末期肾病(ESRD)发作之前就已开始。因此,未来的治疗方法和指南也应强调根据有效临床试验结果,对CKD进行更早检测和管理的必要性。